Target intelligence / Profile preview

NUT family member 2B (NUTM2B)

Target
NUTM2B
Molecular classification
Other (Nuclear protein, involved in gene fusion events), Fusion protein (when translocated/fused with YWHAE in aggressive sarcomas)
01

Overview

NUT family member 2B is a nuclear protein that, by itself, is uncharacterized and part of an understudied gene family. However, when fused to the 14-3-3 protein YWHAE (via chromosomal translocation), it creates an oncogenic fusion protein strongly implicated in aggressive, high-grade endometrial stromal sarcoma (ESS), clear cell sarcoma of the kidney (CCSK), and other soft tissue tumors. The YWHAE-NUTM2B fusion enhances cell proliferation and alters cell cycle regulation by dysregulating key signaling pathways (RAF/MEK/MAPK and Hippo/YAP-TAZ). This fusion is now recognized as an important biomarker for diagnosis and prognosis in several rare pediatric and adult cancers. There is currently no direct therapeutic agent targeting NUT family member 2B or its protein product; its clinical relevance is almost exclusively through oncogenic gene fusions, which are often used for tumor classification and prognosis.

Other names
FAM22BbA119F19.1NUTM2BNUT family member 2Bfamily with sequence similarity 22 member Bprotein FAM22B
02

Mechanism of action

Not directly targeted; oncogenic mechanisms result from gene fusion, which dysregulates cell proliferation via RAF/MEK/MAPK and Hippo/YAP-TAZ pathways

03

Biological functions

Mainly unknown/uncharacterized – NUTM2B is a nuclear protein in testis with poorly described functions on its ownGene fusion partner in cancer, regulating cell proliferation and cyclin D1 expression through RAF/MEK/MAPK and Hippo/YAP-TAZ signaling pathways when fused to YWHAE
04

Disease associations

Cancer (Endometrial stromal sarcoma, Clear cell sarcoma of the kidney, Other soft tissue sarcomas)
05

Safety considerations

No direct safety issues for NUTM2B; clinical management challenges are tied to the aggressiveness of fusion-positive sarcomas and the lack of specific therapies targeting the fusion protein
06

Biomarkers

YWHAE-NUTM2B fusion transcript as a diagnostic and prognostic marker for aggressive endometrial stromal sarcoma and other fusion-driven sarcomas

Beyond the preview

Go deeper on NUT family member 2B (NUTM2B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUT family member 2B (NUTM2B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call